News from abbvie A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 19, 2014, 17:45 ET

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

 The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE:ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with...

Dec 07, 2014, 20:15 ET

AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting

 AbbVie (NYSE: ABBV) presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase...

Nov 21, 2014, 08:00 ET

CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe

 The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for...

Nov 17, 2014, 09:00 ET

AbbVie to Present Data on Investigational Oncology Compounds at the 56th American Society of Hematology Annual Meeting

AbbVie (NYSE: ABBV) will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American...

Nov 17, 2014, 07:00 ET

AbbVie to Present at Jefferies 2014 Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Jefferies 2014 Global Healthcare Conference in London on Thursday, Nov. 20, 2014. Bill Chase,...

Nov 14, 2014, 16:48 ET

AbbVie Presents Results from Study of ABT-414 in Patients with Glioblastoma Multiforme at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

 AbbVie (NYSE: ABBV) released updated interim results from a Phase 1 clinical trial of ABT-414 in patients with glioblastoma multiforme, an...

Nov 13, 2014, 09:00 ET

AbbVie's Leadership in Immunology Featured at 2014 American College of Rheumatology Annual Meeting with New Data on Investigational Medicines and HUMIRA® (adalimumab)

AbbVie (NYSE: ABBV) announced that data from 37 abstracts related to HUMIRA® (adalimumab), rheumatologic diseases and investigational...

Nov 11, 2014, 09:00 ET

AbbVie to Present Results from Studies in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) and Liver Transplant Recipients (CORAL-I) at The Liver Meeting® 2014

 AbbVie (NYSE: ABBV) today announced results from studies in chronic hepatitis C patients with human immunodeficiency virus type 1 (HIV-1)...

Nov 11, 2014, 08:00 ET

AbbVie to Present Results from Phase 2 PEARL-I Study in Genotype 4 Chronic Hepatitis C Patients at The Liver Meeting® 2014

 AbbVie (NYSE:ABBV) announced detailed results from its open-label Phase 2b study, PEARL-I, which demonstrated that 100 percent  of...

Nov 05, 2014, 08:00 ET

AbbVie to Present at Credit Suisse 2014 Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2014 Healthcare Conference on Thursday, Nov. 13, 2014. Bill Chase, executive vice...

Oct 31, 2014, 07:49 ET

AbbVie Reports Third-Quarter 2014 Financial Results

 AbbVie (NYSE: ABBV) today announced financial results for the third quarter ended Sept. 30, 2014. "Our third-quarter results reflect the...

Oct 23, 2014, 08:00 ET

AbbVie Named a Top Employer in Science Magazine's Annual Survey for Second Consecutive Year

AbbVie (NYSE: ABBV) today announced that Science/Science Careers has included AbbVie in its annual Top Employers Survey, as surveyed by more than...

Oct 20, 2014, 17:31 ET

AbbVie Announces New $5 Billion Stock Repurchase Program and Increases Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today authorized a new $5 billion stock repurchase program and increased the company's quarterly...

Oct 20, 2014, 17:12 ET

Announcement Of Termination Of Proposed AbbVie And Shire Transaction

AbbVie Inc. ("AbbVie") and Shire plc ("Shire") have agreed to terminate their proposed merger following the decision by AbbVie's Board to...

Oct 15, 2014, 23:53 ET

AbbVie Board Recommends Stockholders Vote Against Shire Transaction

Following Shire plc's ("Shire") waiver of the three-day notice period, AbbVie Inc. ("AbbVie") (NYSE: ABBV) announces today its Board of...

Oct 14, 2014, 19:44 ET

Announcement Of Notice To Shire Of AbbVie Board Intention To Reconsider Recommendation

AbbVie Inc. ("AbbVie") announces it has notified Shire plc ("Shire") of its Board of Directors' intention to reconsider the recommendation made on...

Oct 13, 2014, 11:43 ET
http://www.multivu.com/players/English/7298751-abbvie-phase-3-hidradenitis-suppurativa-trial-results/gallery/image/f1f12d6c-637d-46c9-8c65-812b7bf1c884.HR.jpg

AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress

AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab)  in...

Oct 06, 2014, 08:00 ET
Oct 01, 2014, 10:05 ET

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...

Sep 27, 2014, 06:45 ET

AbbVie Presents Results from Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress

 AbbVie (NYSE: ABBV) released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with...